Regeneron Pharmaceuticals (REGN) has won Food and Drug Administration approval for a new cancer therapy, lining up behind five marketed treatments that work by removing brakes on the immune system to turn the body’s defenses against tumors.

The company, alongside partner Sanofi (SNY), is entering a crowded market in which it is years behind the leaders, who have reaped billions of dollars in sales while racking up FDA approvals in more than a dozen tumor types. But Regeneron believes that, with some clever positioning and combination treatments, it can outfox its rivals and build its drug, cemiplimab, into a contender in the field.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy